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Background: SARS-CoV-2 is an RNA virus causing COVID-19. The clinical
characteristics and epidemiology of COVID-19 have been extensively investigated,
however, only one study so far focused on the patient’s nasopharynx microbiota.
In this study we investigated the nasopharynx microbial community of patients that
developed different severity levels of COVID-19. We performed 16S ribosomal DNA
sequencing from nasopharyngeal swab samples obtained from SARS-CoV-2 positive
(56) and negative (18) patients in the province of Alicante (Spain) in their first visit to
the hospital. Positive SARS-CoV-2 patients were observed and later categorized in mild
(symptomatic without hospitalization), moderate (hospitalization), and severe (admission
to ICU). We compared the microbiota diversity and OTU composition among severity
groups and built bacterial co-abundance networks for each group.
Results: Statistical analysis indicated differences in the nasopharyngeal microbiome of
COVID19 patients. 62 OTUs were found exclusively in SARS-CoV-2 positive patients,
mostly classified as members of the phylum Bacteroidota (18) and Firmicutes (25). OTUs
classified as Prevotella were found to be significantly more abundant in patients that
developed more severe COVID-19. Furthermore, co-abundance analysis indicated a
loss of network complexity among samples from patients that later developed more
severe symptoms.
Conclusion: Our study shows that the nasopharyngeal microbiome of COVID-19
patients showed differences in the composition of specific OTUs and complexity of co-
abundance networks. Taxa with differential abundances among groups could serve as
biomarkers for COVID-19 severity. Nevertheless, further studies with larger sample sizes
should be conducted to validate these results.
Keywords: COVID-19, SARS-CoV-2, microbiome, NGS – next generation sequencing, coronavirus, Prevotella
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IMPORTANCE
This work has studied the microbiota of the nasopharyngeal
tract in COVID-19 patients using advanced techniques of
molecular microbiology. Diverse microorganisms, most of which
are harmless or even beneficial to the host, colonize the
nasopharynx. However, changes in this microbiota could be
related with different diseases such as cancer, gastrointestinal
pathologies or even COVID-19. This study investigated the
microbiota from patients with COVID-19, in order to determine
its associations with pathology severity. The obtained results
revealed several bacterial taxa with differential abundance
among COVID-19 cases. This study represents the first step
to understand the associations between microbiota composition
and the severity of COVID-19.
BACKGROUND
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) is a positive-sense single-stranded RNA virus causing
Coronavirus Disease 2019 (COVID-19) (Andersen et al., 2020).
On January 30, 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak as “public health emergency
of international concern” and 2 months later on March 11th
as a pandemic. The SARS-CoV-2 virus was first reported in
central city of Wuhan, Hubei province, China, and presented 70%
of sequence similarity with the SARS-CoV-1 virus (Zhu et al.,
2020) and 96% of sequence similarity with a bat coronavirus,
although the exact source has yet to be elucidated. While the
most common symptoms are fever, cough and dyspnoea, the
disease can cause other less frequent clinical manifestations
such as myalgia, headaches, breathlessness, fatigue and nausea
(Guan et al., 2020).
Viruses and bacteria are often present in the respiratory tract
of healthy and asymptomatic individuals. Microaspiration of
aerosols and direct mucosal dispersal is responsible for a constant
inflow of microbes and viruses toward lower airways. Disease and
inflammatory processes that lead to the emergence of anaerobic
zones, or mucus accumulation in the alveoli can drastically
change the microbial community of the airways (Huffnagle et al.,
2017). For example, in diseased individuals, the lung microbiota
composition undergoes a decrease in diversity (Kalantar et al.,
2019) accompanied by a shift in the dominant taxa: from
Bacteroidota to Gammaproteobacteria, a class that includes many
respiratory pathogens.
Although the clinical characteristics and epidemiology of
COVID-19 have been described (Chen N. et al., 2020; Rothan
and Byrareddy, 2020; Wu et al., 2020), studies focused on the
associations between the patient’s microbiota and the onset of
the disease are still limited. This pilot study aims to characterize
the nasopharynx microbial community of SARS-CoV-2 infected
patients. We investigated samples from a control group of
SARS-CoV-2 negative patients and three groups of SARS-CoV-2
positive patients, divided according to disease severity: one group
of symptomatic patients that did not require hospitalization, a
second group of patients that were admitted to conventional
hospitalization facilities, and a third group of patients that
required admission to the ICU.
MATERIALS AND METHODS
Patients and Experimental Design
Fifty six nasopharyngeal microbiota samples from SARS-CoV-
2 positive patients and 18 samples from SARS-CoV-2 negative
patients were collected during March and April of 2020 in the
Emergency Service of Hospital General Universitario de Alicante
(HGUA). The samples were collected in a sterile tube containing
Viral Transport Medium using a nasal swap, and they were stored
at –80◦C until the DNA/RNA extraction. Cobas SARS-CoV-2
qPCR Test for the Cobas 6800 System (Roche Molecular Systems,
Branchburg, NJ, United States) was used to detect the presence of
SARS-CoV-2 and to obtain de Ct Values (Poljak et al., 2020). The
Table 1 describes the groups of patients regarding sex, age, and
clinical variables.
Patients were first classified based on SARS-CoV-2 presence,
and then regarding on later developments (hospital admission
and severity). All samples were obtained before the onset of
severe symptoms, and before any treatment was administered
to the patients. Following these criteria, four groups were
established: group 0: SARS-CoV-2 negative patients (n = 18);
group 1: mild COVID-19 symptoms but no later hospital
admission (n = 19); group 2: severe COVID-19 symptoms
followed by hospital admission (n = 18); and group 3:
patients with severe COVID-19 symptoms which were eventually
admitted into intensive care units (ICU) (n = 19). Protocols
were developed in accordance with the national ethical and
legal standards, and following the guidelines established in
the Declaration of Helsinki (2000). The research project (Ref:
COV20_00236) was conducted under the written approval of the
Ethic Committee of Clinical Research with Drug (in Spanish,
CEIm) of the “Hospital General Universitario de Alicante
(Spain)”(Ref CEIm approval: PI2020-052), and in collaboration
with the Biobank of Clinical and Biomedical Research Institute
of Alicante (ISABIAL), which are included in the Valencian
Network of Biobanks. All samples and clinical data of patients
were managed anonymously.
DNA Isolation and Sequencing
DNA from nasopharyngeal swab samples was isolated using
the QIAamp DNA Mini Kit (QIAgen) following the protocol
recommended by the manufacturer. Sequencing libraries were
prepared according to the 16S Metagenomic Sequencing Library
Preparation protocol distributed by Illumina. Briefly, the
sequence spanning the hypervariable regions V3 and V4 of
the 16S rRNA gene was amplified through PCR. Amplicons
were quantified using a Qubit 4 Fluorometer (Qubit dsDNA HS
Assay Kit) validated by 4200 TapeStation (Agilent company).
Amplicons were sequenced with Illumina MiSeq System using
the 2 × 300 bp cartridge. The quality of raw sequences was
assessed by FastQC software.
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TABLE 1 | Descriptive data from severity groups.
Group 0 (N = 18) Group 1 (N = 19) Group 2 (N = 18) Group 3 (N = 19) Total (N = 74)
Age
-Mean (SD) 48.111 (19.244) 59.526 (22.860) 66.833 (13.781) 66.263 (12.458) 60.257 (18.819)
-Range 13.000–86.000 23.000–94.000 46.000–91.000 40.000–85.000 13.000–94.000
Gender
-F 9 (50.0%) 12 (63.2%) 9 (50.0%) 2 (10.5%) 32 (43.2%)
-M 9 (50.0%) 7 (36.8%) 9 (50.0%) 17 (89.5%) 42 (56.8%)
Hospital admission
-No 18 (100.0%) 19 (100.0%) 0 (0.0%) 0 (0.0%) 37 (50.0%)
-Yes 0 (0.0%) 0 (0.0%) 18 (100.0%) 19 (100.0%) 37 (50.0%)
Diagnosis
-Bronchitis 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
-COPD* 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
-Fever 0 (0.0%) 2 (10.5%) 0 (0.0%) 0 (0.0%) 2 (2.7%)
-Pneumonia 2 (11.1%) 4 (21.1%) 14 (77.8%) 15 (78.9%) 35 (47.3%)
-Respiratory infection 8 (44.4%) 11 (57.9%) 4 (22.2%) 0 (0.0%) 23 (31.1%)
-Respiratory insufficiency 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (21.1%) 4 (5.4%)
-RSC-COVID19** 6 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (8.1%)
-Toracic pain 0 (0.0%) 1 (5.3%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
-Vomits 0 (0.0%) 1 (5.3%) 0 (0.0%) 0 (0.0%) 1 (1.4%)
Intensive units
-No 18 (100.0%) 19 (100.0%) 18 (100.0%) 0 (0.0%) 55 (74.3%)
-Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 19 (100.0%) 19 (25.7%)
Ct (cycle threshold)
-Mean (SD) 26.34 (5.17) 27.03 (5.31) 25.86 (4.69) 26.38 (5.07)
*COPD: Chronic obstructive pulmonary disease.
**RSC-COVID19: Respiratory symptoms compatible with COVID19 disease.
Taxonomic Classification of Amplicon
Sequences
Paired end reads of 300 bp were generated with an average
overlap of 140 bp. Sequences were trimmed using trimmomatic
(Bolger et al., 2014) to clip out low-quality nucleotides at the
read ends and to remove sequences that, after trimming, one of
the paired-end reads was smaller than 150 bp and the resulting
paired reads were merged using casper (Kwon et al., 2014),
generating individual fragments of about 460 bp. Given the
uneven coverage between samples, the number of individual
reads was standardized to 20,000 per sample, removing samples
that did not reach this sequencing depth (9 samples). Total
number of reads and cycle threshold (Ct) per sample is shown
in Supplementary Table S1. Merged amplicon sequences were
grouped in operational taxonomic units (OTUs) using cd-hit (Fu
et al., 2012) with an identity of 97%. Sequences were queried
against small subunits (16S) rRNA genes of the SILVA database
(version 138, Reference subset) (Quast et al., 2013) using the
SILVA Incremental Aligner (SINA) software (Pruesse et al., 2012)
for taxonomic classification. Sequences with low identity (<70%)
to any reference 16S rRNA gene or classified as eukaryotic were
excluded from further analysis.
Testing for Differences in Taxonomic
Composition Among Patient Groups
We sought to determine how different samples were grouped
according to their OTU composition. To that end, the
Vegan (v 2.5-6) package available in R (v 3.6.3) was used
to perform a non-metric multidimensional scaling (NMDS)
analysis on Bray-Curtis dissimilarity measures among samples
based on relative OTU abundances (i.e., percentages). The
relative abundances of OTUs were also used to test for
statistically significant differences among severity groups. Group
OTU compositions were compared through ANOSIM. Next,
Similarity Percentage (SIMPER) analysis was used to determine
which OTUs were responsible for driving the differences in
community composition among groups. For this analysis,
all six possible pairwise combinations of severity groups
were tested.
OTU Association With COVID-19 Severity
To infer associations between the severity of COVID-19 and
the nasopharynx microbiota, general linear models (GLM)
were built using the R package MaAsLin2 with centered
log-transformed (CLR) OTUs counts as the dependent
variable, and the severity group (with group 0 and group 1
as references), as independent variable. Due to the differences
of age and sex between groups, we adjusted by sex and
age. Only OTUs that presented a prevalence of 20% over
the sample space were considered. The resulting p-values
were adjusted for multiple testing using the Benjamini-
Hochberg method (BH). The analysis was replicated
using QIIME2 (Bolyen et al., 2019) together with LEfSE
(Linear discriminant analysis Effect Size) and included as a
Supplementary Material.
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Co-abundance Networks for COVID-19
Severity Groups
Fastpar (Watts et al., 2019), a multi-thread implementation
of the SparCC algorithm (Friedman and Alm, 2012), was
used to generate co-abundance networks among OTUs of
each of the four severity groups with default parameters (50
iterations and correlation threshold of 0.2) and 1,000 bootstrap
iterations to infer significance. Results were processed using an
in-house ipython notebook to generate network matrices for
visualization with Cytoscape 3.8 (Shannon et al., 2003). The
network matrices were loaded in the Cytoscape 3.8 software,
and connections filtered by p-value (≤0.05) and correlation
(≤0.6 or ≥0.6).
RESULTS
Study Set of COVID-19
Seventy-four patients were included in this pilot study to
assess associations between the nasopharyngeal microbiota
composition and the severity of the COVID-19 disease. However,
only 65 samples remained after quality coverage control
(see section “Materials and Methods”). Data including age,
sex, diagnosis, hospital admission, and disease severity were
registered (Supplementary Table S2). Sixteen patients belonged
to the negative control (group 0, no-SARS-CoV-2), whereas the
remaining patients were classified into three groups (group 1,
2, and 3) according to the severity (see section “Materials and
Methods”). The average age of the patients ranged from 48.1 years
old (group 0) to 66.8 years old (group 2) and around 49% of them
were diagnosed with pneumonia (Table 1).
Microbiota Taxonomic Composition
Differs Among Severity Groups of
COVID-19
The bacterial phylum Firmicutes was the most abundant
in the nasopharynx microbiota among patients from all
severity groups (52.9% ± 4.0%), followed by Bacteroidota
(22.1% ± 6.1%), Proteobacteria (12.7% ± 7.3%), and
Actinobacteria (5.4% ± 0.6%). At the genus level, Streptococcus
was the most abundant taxon (25.2% ± 2.0%), followed
by Prevotella (16.2% ± 5.7%), Veillonella (14.4% ± 2.2%),
Haemophilus (5.23% ± 4.78%), and Moraxella (3.2% ± 3.6%)
(Supplementary Figure S1 and Supplementary Table S3).
A total of 62 OTUs were found exclusively in SARS-CoV-2
positive patients (at a minimum of three samples). Most of these
OTUs were classified as members of the phylum Bacteroidota
(18) and Firmicutes (25). Notably, the most common genera
among the OTUs found exclusively on COVID-19 positive
patients were Prevotella (13), followed by Leptotrichia (4) and
Streptococcus (4). Samples were compared based on the relative
abundances of OTUs. This analysis revealed that samples did not
cluster according to the severity group neither by hierarchical
clustering (Figures 1A,B) or NMDS (Figure 1C). Nevertheless,
the differences in OTU composition among severity groups were
significant according to ANOSIM (R = 0.046, p = 0.036).
SIMPER analysis revealed that 25 OTUs were responsible
for approximately 70% (p-value 0.04) of the differences in
community composition between severity groups 1 and 3
(Supplementary Table S4). These OTUs were classified as
members of the phyla Bacteroidotas, Firmicutes, Fusobacteriota,
and Proteobacteria. Eleven OTUs had higher average abundance
among samples from severity group 1, among which were
included three OTUs classified as members of the genus
Veillonella. On the other hand, 14 OTUs were more abundant
among samples from severity group 3, among which were
included four OTUs classified as Prevotella.
Multiple OTUs Display Differential
Abundance According to COVID-19
Severity
Using MaAsLin2 and group 0 as a reference, we identified a
total of 10 significant associations between bacterial OTUs and
patient severity (p < 0.05, q < 0.25), corrected for age and sex.
Among those, 9 were positively associated (8 in group 2 and
1 in group 3 when contrasted with group 0) and 1 negatively
associated (in group 3 contrasted with group 0) (Supplementary
Table S5 and Figure 2A). Of the OTUs positively associated with
severity, three were classified as members of the genus Prevotella
(OTUs 4, 14, and 16). Due to the heterogeneity of group 0,
we also decided to investigate the differences within the SARS-
CoV-2 positive patients, using group 1 as reference. The GLM
model showed just 1 significant OTU (OTU 16), a Prevotella
also found to be significantly associated with severity in the first
model (Supplementary Table S5 and Figure 2B). In the same
line, the results obtained with QIIME2 using the q2-composition
plugin, and with LEfSE method showed that Prevotella sp. was
associated with patient severity (Supplementary Figure S2). We
did not find any OTUs significantly different between groups 1
and 0. Figure 2A shows the coefficients for all the significant
OTUs found by both GLMs and Figure 2B shows OTU 16 CLR
transformed counts for all severity groups.
Co-abundance Networks for COVID-19
Severity Groups
In order to investigate how OTUs correlate within the different
groups, we generated a total of 4 co-abundance networks, one
for each severity group. For the severity group 0, the SARS-
CoV-2 negative group, the network displayed 118 nodes with 179
edges. Regarding the other three severity groups, ranging from
mild to high severity, the complexity of the network decreased
with the increase of severity. The network for patients with mild
symptoms (group 1) had 137 nodes with 457 edges, while the
network for patients with severe symptoms but not admitted in
ICU (group 2) had 129 nodes with 171 edges. The network for
severe patients admitted in ICU (group 3) had 100 nodes and 148
edges. In the network of severity group 1, OTU 16 (Prevotella,
associated with severity in two GLMs) displayed 18 co-abundant
OTUs connected in the network in first degree (Figure 3). Among
these connections, ten were negative associations while eight
were positive. Most of these connections with OTU 16 were
absent from networks of severity groups 2 and 3. Only 3 and
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FIGURE 1 | Beta diversity. Dendrogram based on (A) Bray-Curtis dissimilarity and (B) Sørensen dissimilarity values. (C) Comparison of sample taxonomic profiles by
severity group. Non-metric multidimensional scaling was applied to determine the clustering patterns of samples according to their OTU abundance patterns. Each
dot represents a sample color coded according to the severity group it belongs to. The closer the samples are, the more similar was their OTU abundance
composition. No clear clustering of samples by severity group was observed.
2 first degree connections remained in each of these networks,
respectively (Supplementary Figure S3).
DISCUSSION
In this preliminary study, the analysis of the taxonomic
composition of the samples showed differences between
patients that developed different onsets of COVID-19.
Previously, only one study was conducted to investigate
the nasopharynx microbiota of COVID-19 patients (Maio
et al., 2020). This study did not find any differences
between patients and controls. However, this study was
conducted only in two groups, the control and mild
COVID-19 patients.
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FIGURE 2 | (A) Error bar plot of the GLM coefficients interval for each OTU. The Y-axis shows the OTU number and Genus classification. The X-axis represents the
CLR abundance variance explained by the GLM models. In red the positively associated OTUs with severity state (ranging from group 1 to 3) and in blue OTUs the
negatively associated with severity state OTUS. (B) The centered log- transformed (CLR) OTU 16 (Prevotella) abundance in the severity groups 0–3, showing its
higher abundance in severity categories.
FIGURE 3 | Co-abundance network (severity group 1) showing only first-degree neighbors of OTU 16 (Prevotella sp.). OTUs are represented by nodes and
significant correlations by edges. Blue edges represent negative associations and red, positive associations. The color of nodes was defined by the taxonomic
classification of the OTU at Genus rank.
In our study, we found subtle changes in nasopharyngeal
community composition, meaning that they are restricted to few
taxa out of the complete meta-community. Nevertheless, there
are detectable and significant changes among OTU abundances.
These changes could be linked to the different severity groups,
as we identified both taxa that were present exclusively among
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COVID-19 positive patients as well as those whose abundance
was significantly higher or lower among different severity groups.
Not only this, but also the complexity of co-abundance networks
(which can be taken as a proxy for potential interactions between
taxa), was decreased among patients that developed more severe
cases of COVID-19. Below we discuss the mechanisms by which
specific microbes might play a role in either enhancing or
decreasing the severity of COVID-19.
Potential Associations Between
Bacterial Taxa and COVID-19 Severity
Among the OTUs positively associated with COVID-19 severity,
three were classified as members of the genus Prevotella, and one
to a closely related genus, Alloprevotella. A recent study showed
that Prevotella proteins can promote viral infection through
multiple interactions with NF-κB signaling pathway, which is
also involved in COVID-19 severity (Khan and Khan, 2020).
The genus Prevotella is usually considered commensal and, as
such, rarely involved in infections. However, some strains have
been identified as opportunistic pathogens in chronic infections,
abscesses and anaerobic pneumonia (Brook, 1998; Brook, 2004;
Nagy, 2010; Larsen, 2017). The role of some strains of Prevotella
in chronic mucosal inflammation has been demonstrated. They
are involved with augmented T helper type 17 (Th17)-mediated
mucosal inflammation, through activation of Toll-like receptor
2, followed by production of cytokines by antigen-presenting
cells, including interleukin-23 (IL-23) and IL-1 (Larsen, 2017).
The severe symptoms of COVID-19 are associated with cytokine
storms, many of which are involved in TH17 type responses
(Wu and Yang, 2020). The significant association of Prevotella
sp. and disease severity observed here suggests a possible link
between Prevotella sp. and the COVID-19 through the activation
of immunity signaling pathways that modulate inflammation,
and this link should be further explored.
Reduced Network Complexity Among
Patients Who Later Developed More
Severe COVID-19
Several studies demonstrated the usefulness of co-abundance
networks to elucidate changes in the microbiota associated
with human diseases (Faust et al., 2012; Greenblum et al.,
2012; Wang et al., 2016; Chen L. et al., 2020). By switching
from individual OTU associations to a community interaction
approach it is possible to attain a better understanding of
the dynamic of microbiota/phenotype associations, revealing
microbial consortia (and not only an OTU) that might be
collectively influencing the host phenotype. Our linear models
showed OTU 16 (Prevotella sp.) as an important OTU associated
with severity. This OTU had the highest number of connections
in the network, followed by OTU 9 (Veillonella sp.). Of
the four networks generated, the severity group 1 network
showed the higher number of interactions with this OTU.
Ecological networking, in vitro, and clinical studies showed
that Prevotella sp. and Veillonella sp. are keystone species in
the microbiota during airway disease progression, especially
in diseases associated with mucus accumulation such as cystic
fibrosis (Flynn et al., 2016; Quinn et al., 2016; Silveira et al., 2020).
These anaerobes are efficient at degrading mucin molecules
on the airway mucosa, releasing by-products that enable the
colonization and growth of pathogenic bacteria that are poor at
degrading mucus for growth (Flynn et al., 2020). In COVID-19
patients, Prevotella sp. and Veillonella sp. could have a similar
role due to the decreased mucociliary clearance caused by the
viral infection (Robinot et al., 2020). Lower rates of clearing
increase the residence time of Prevotella sp. and Veillonella sp.
in the airways, likely increasing their mucus metabolism and
enabling further colonization by pathogenic bacteria that may
cause pneumonia.
OTU 96, classified as Dolosigranulum sp., was identified in the
group 1 network and displayed a negative association with OTU
16 (Prevotella sp.) as a first-degree neighbor (Figure 3). OTU
96 did not pass the q-value threshold established for the GLMs
but shows significant p-value (0.003 in the model comparing
group 2 and group 0, and 0.02 in the model comparing group 2
and group 1 as reference). The only species currently described
in this genus is Dolosigranulum pigrum, which is commonly
found in the nasopharynx microbiota and is predicted to benefit
the host through protection against pneumococcal colonization
(Biesbroek et al., 2014; Bomar et al., 2016) and through protection
against inflammation damage (Moyano et al., 2020). One study
also found a lower abundance of Dolosigranulum in children
with Influenza A Virus compared to healthy children (Wen
et al., 2018). In addition, a study reported that patients with
their airway microbiota dominated by Corynebacterium and
Dolosigranulum experienced the lowest rates of early loss of
asthma control and have a longer time to develop at least 2
episodes (Zhou et al., 2019). We did not identify Corynebacterium
directly connected to OTU 16 (Prevotella sp.), but OTU 78,
classified as Corynebacterium is positively associated with OTU
96 (0.7479, p = 0.001) in the co-abundance network from group
1 (Figure 3), indicating that in asymptomatic patients those
two taxa are forming a consortium that might protect from
disease development. This “consortium” was also implicated in
resistance to recurrent ear infections and it was proposed as a
probiotic candidate for upper respiratory tract infections (Lappan
and Peacock, 2019). The reason that we did not have lower
q-value in our GLM for those two taxa could be the lack of
power due to the small size of our study. Thus, these associations
warrant further investigation.
LIMITATIONS
The major limitation of our study is the small sample size.
With only about 15 samples per severity group it is difficult
to find statistically significant associations between microbiota
composition and disease severity. Nevertheless, this limitation is
more likely to lead to false negatives than to false positives. We
also cannot rule out confounding factors that might explain the
differences between groups, and the fact that many patients of the
control group were diagnosed with other respiratory infections
or pneumonia, which could have influenced their microbiota in
a manner unrelated to COVID-19. Another important limitation
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is the fact that we performed amplicon rather than whole genome
shotgun sequencing. This leads to three issues. First, some of
the bacterial diversity is lost due to the fact that the selected
primers do not amplify the entirety of bacterial diversity. Second,
some genomes have more than a single copy of the 16S operon,
which can lead to an overestimation of their abundance in
the samples. Third, without metagenomes (and metagenome-
assembled genomes) we could not make inferences about the
presence of virulence factors and other features of the genomes
of the microbes in our samples. We resorted to 16S amplification
because our non-invasive approach to collect samples yields low
DNA amounts that are inadequate for sequencing. However, as
far as we know, this is a unique pilot study in the field. The aim
is to be able to transfer useful results to help clinical practice
in the fight against the virus and to optimize all the protocols
and analyses for a second analysis in which the sample size will
be much larger. We are currently working on collecting more
samples and optimizing protocols that will allow us to obtain
whole genome shotgun sequencing from them.
CONCLUSION
Our data provides preliminary evidence of significant differences
in the composition of the upper airway microbiota according to
COVID-19 severity, suggesting potential biomarkers of disease
severity. While the richness and diversity indexes did not
show significant differences among groups, specific taxa were
significantly associated with disease development. We also
demonstrated that the complexity of the co-abundance network
is decreased in patients who came to develop severe cases of
the disease, indicating that the interactions between the taxa are
also relevant to this process. Further studies will be necessary to
shed light on the molecular mechanisms that give rise to these
associations. Finally, we make no claim that the differences in
microbiota composition reported here are the cause of COVID-
19 severity. Nevertheless, the significant associations found
between these variables suggests that the role of the microbiota
on the onset of disease severity warrants further investigation.
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